✦ LIBER ✦

Persistence of antibodies after immunization with a recombinant yeast-derived hepatitis B vaccine following two different schedules

✍ Scribed by N. Scheiermann; M. Gesemann; C. Maurer; M. Just; R. Berger

Book ID: 119150781
Publisher: Elsevier Science
Year: 1990
Tongue: English
Weight: 222 KB
Volume: 8
Category: Article
ISSN: 0264-410X
DOI: 10.1016/0264-410x(90)90217-a

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Persistence of antibodies following vacc

Persistence of antibodies following vaccination with a yeast-derived recombinant hepatitis B vaccine

✍ M. Just; R. Berger; N. Scheiermann 📂 Article 📅 1988 🏛 Elsevier Science 🌐 English ⚖ 139 KB

Persistence of immunity and seroprotecti

Persistence of immunity and seroprotection 4 years after a primary vaccination schedule with a Hansenula polymorpha recombinant hepatitis B vaccine

✍ A Lepetic; C Biscayart; M Seigelchifer; R Arduino; D Stamboulian 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 91 KB

Two different dosages of yeast derived r

Two different dosages of yeast derived recombinant hepatitis B vaccines: a comparison of immunogenicity

✍ M. Chiaramonte; S. Majori; T. Ngatchu; M.E. Moschen; V. Baldo; G. Renzulli; I. S 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 296 KB

Long-term persistence of anti-HBs after

Long-term persistence of anti-HBs after vaccination with a recombinant DNA yeast-derived hepatitis B vaccine: 8-year results

✍ Koen Van Herck; Pierre Van Damme; Stefan Thoelen; André Meheus 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 405 KB

Immunogenicity of a recombinant, yeast-d

Immunogenicity of a recombinant, yeast-derived, anti-hepatitis-B vaccine after alternative dosage and schedule vaccination in Pakistani children

✍ Dure Samin Akram; Sajid Maqbool; Dure Shawar Khan; Rafat Jafri; Sajid Randhawa; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 102 KB

Characterization of a human monoclonal a

Characterization of a human monoclonal antibody obtained after immunization with plasma vaccine and a booster with recombinant-DNA hepatitis B vaccine

✍ R.A. Heijtink; J. Kruining; P. van Bergen; S. de Rave; J. van Hattum; M. Schutte 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 204 KB

A human monoclonal antibody type IgG4, designated 1Ff4, was obtained by Epstein Barr virus transformation of peripheral blood lymphocytes from a hepatitis B vaccinee (HB-VAX: plasmaderived vaccine) after one boost of yeast recombinant DNA derived vaccine (Engerix-B). 1Ff4 binds preferentially to HBs